|
Variables
|
Nt (%)
|
Ne (%)
| |
LC-SM (%)
| | |
OCSM (%)
| |
|---|
|
3-year (95% CI)
|
5-year (95% CI)
|
P
|
3-year (95% CI)
|
5-year(95% CI)
|
P
|
|---|
|
Total
|
2705
|
1897
|
49.6 (47.7–51.5)
|
55.8 (53.8–57.8)
| |
8.2 (7.1–9.2)
|
11.8 (10.5–13.1)
| |
|
Age (years)
|
|
median (IQR)
|
69 (61–76)
|
70 (62–77)
| | | | | | |
|
< 65 years
|
929 (34.3)
|
608 (32.1)
|
49.2 (45.9–52.4)
|
55.0 (51.6–58.3)
|
0.275
|
5.1 (3.7–6.5)
|
8.0 (6.2–9.9)
|
< 0.001
|
|
≥ 65 years
|
1776 (65.7)
|
1289 (67.9)
|
49.9 (47.5–52.2)
|
56.3 (53.8–58.7)
| |
9.8 (8.4–11.2)
|
13.9 (12.2–15.6)
| |
|
Sex
| | | | |
0.002
| | |
0.421
|
|
Female
|
1268 (46.9)
|
858 (45.2)
|
45.8 (43.0–48.6)
|
52.4 (49.5–55.3)
| |
8.3 (6.8–9.9)
|
11.9 (10.0–13.8)
| |
|
Male
|
1437 (53.1)
|
1039 (54.8)
|
53.0 (50.4–55.6)
|
58.8 (56.1–61.5)
| |
8.0 (6.6–9.5)
|
11.8 (10.0–13.6)
| |
|
Race
| | | | |
0.008
| | |
0.027
|
|
Black
|
262 (9.7)
|
195 (10.3)
|
56.8 (50.7–63.0)
|
62.9 (56.7–69.1)
| |
7.0 (3.9–10.2)
|
12.4 (8.0–16.8)
| |
|
White
|
2248 (83.1)
|
1571 (82.8)
|
48.4 (46.3–50.5)
|
54.4 (52.2–56.6)
| |
8.6 (7.4–9.8)
|
12.2 (10.8–13.7)
| |
|
Other race
|
195 (7.2)
|
131 (6.9)
|
54.3 (46.9–61.7)
|
63.1 (55.6–70.6)
| |
4.3 (1.4–7.3)
|
6.0 (2.3–9.7)
| |
|
Marital status
| | | | |
0.018
| | |
0.455
|
|
Married
|
1590 (58.8)
|
1091 (57.5)
|
48.1 (45.5–50.6)
|
54.2 (51.6–56.8)
| |
7.9 (6.5–9.2)
|
11.3 (9.7–13.0)
| |
|
Unmarried
|
1115 (41.2)
|
806 (42.5)
|
51.9 (48.9–54.9)
|
58.1 (55.1–61.2)
| |
8.6 (6.9–10.3)
|
12.6 (10.5–14.7)
| |
|
Tumour site
| | | | |
< 0.001
| | |
0.213
|
|
Upper lobe
|
1651 (61.0)
|
1130 (59.6)
|
47.8 (45.3–50.3)
|
53.7 (51.2–56.3)
| |
8 (6.7–9.4)
|
12 (10.3–13.7)
| |
|
Middle lobe
|
113 (4.2)
|
79 (4.2)
|
42.4 (33.1–51.7)
|
53.8 (43.7–63.8)
| |
11.2 (5.1–17.2)
|
18.6 (10.6–26.6)
| |
|
Lower lobe
|
838 (31.0)
|
605 (31.9)
|
52.3 (48.8–55.7)
|
58.2 (54.7–61.7)
| |
8.5 (6.5–10.4)
|
11.4 (9.1–13.7)
| |
|
Main bronchus
|
58 (2.1)
|
53 (2.8)
|
82 (71.6–92.5)
|
86.8 (76.9–96.7)
| |
5.2 (0–11)
|
5.2 (0–11.0)
| |
|
Overlapping lesion
|
45 (1.7)
|
30 (1.6)
|
42.8 (28–57.6)
|
52.8 (37.5–68.0)
| |
4.6 (0–11)
|
7.1 (0–15.0)
| |
|
Tumour laterality
| | | | |
0.131
| | |
0.165
|
|
Right
|
1564 (57.8)
|
1105 (58.2)
|
48.7 (46.2–51.2)
|
55.2 (52.6–57.8)
| |
8.6 (7.2–10)
|
12.9 (11.1–14.7)
| |
|
Left
|
1135 (42.0)
|
787 (41.5)
|
50.8 (47.9–53.8)
|
56.4 (53.4–59.4)
| |
7.6 (6–9.2)
|
10.4 (8.5–12.3)
| |
|
Bilateral
|
6 (0.2)
|
5 (0.3)
|
66.7 (22.2–111.2)
|
83.3 (43.8–100)
| |
0 (0–0)
|
0 (0–0)
| |
|
Grade
| | | | |
< 0.001
| | |
< 0.001
|
|
Grade I
|
35 (1.3)
|
21 (1.1)
|
21.1 (6.8–35.3)
|
21.1 (6.8–35.3)
| |
21.5 (7–36)
|
25.6 (9.6–41.5)
| |
|
Grade II
|
857 (31.7)
|
529 (27.9)
|
38.2 (34.8–41.5)
|
45.9 (42.4–49.5)
| |
7.5 (5.7–9.3)
|
12.8 (10.4–15.3)
| |
|
Grade III
|
1751 (64.7)
|
1294 (68.2)
|
55.4 (53.1–57.8)
|
61.1 (58.7–63.5)
| |
8.3 (6.9–9.6)
|
11.1 (9.5–12.6)
| |
|
Grade IV
|
62 (2.3)
|
53 (2.8)
|
60.1 (47.7–72.6)
|
62.1 (49.6–74.6)
| |
8.2 (1.2–15.2)
|
12.2 (3.5–20.8)
| |
|
T stage
| | | | |
< 0.001
| | |
< 0.001
|
|
T1
|
736 (27.2)
|
402 (21.2)
|
26.8 (23.5–30.1)
|
32.8 (29.2–36.4)
| |
9.4 (7.2–11.6)
|
16.3 (13.3–19.2)
| |
|
T2
|
1213 (44.8)
|
839 (44.2)
|
47.2 (44.4–50.1)
|
54.2 (51.3–57.2)
| |
9 (7.4–10.7)
|
12.1 (10.2–14.0)
| |
|
T3
|
211 (7.8)
|
174 (9.2)
|
68.9 (62.5–75.3)
|
74.6 (68.4–80.9)
| |
6.6 (3.1–10.1)
|
9.9 (5.5–14.4)
| |
|
T4
|
545 (20.1)
|
482 (25.4)
|
78.2 (74.6–81.7)
|
83.1 (79.7–86.5)
| |
5.2 (3.3–7.1)
|
6.1 (4.0–8.2)
| |
|
N stage
| | | | |
< 0.001
| | |
< 0.001
|
|
N0
|
1475 (54.5)
|
892 (47.0)
|
33.8 (31.4–36.3)
|
40.6 (38.0–43.2)
| |
9.6 (8–11.1)
|
14.9 (12.9–16.9)
| |
|
N1
|
362 (13.4)
|
245 (12.9)
|
51.5 (46.2–56.7)
|
58.6 (53.2–64.0)
| |
5.6 (3.1–8)
|
8.3 (5.2–11.4)
| |
|
N2
|
711 (26.3)
|
617 (32.5)
|
73.8 (70.5–77.1)
|
79.2 (76.0–82.3)
| |
7 (5.1–8.9)
|
8.3 (6.2–10.4)
| |
|
N3
|
157 (5.8)
|
143 (7.5)
|
85.1 (79.2–91.0)
|
87.3 (81.5–93.2)
| |
6.6 (2.6–10.5)
|
6.6 (2.6–10.5)
| |
|
M stage
| | | | |
< 0.001
| | |
< 0.001
|
|
M0
|
2108 (77.9)
|
1344 (70.8)
|
39.8 (37.7–42)
|
46.9 (44.7–49.2)
| |
8.9 (7.6–10.1)
|
13.3 (11.8–14.9)
| |
|
M1
|
597 (22.1)
|
553 (29.2)
|
84.2 (81.2–87.1)
|
87.1 (84.2–89.9)
| |
5.8 (3.9–7.7)
|
6.5 (4.5–8.6)
| |
|
AJCC Stage
| | | | |
< 0.001
| | |
< 0.001
|
|
I
|
1142 (42.2)
|
624 (32.9)
|
23.9 (21.4–26.4)
|
31.1 (28.3–34.0)
| |
11.2 (9.3–13.1)
|
17.2 (14.8–19.6)
| |
|
II
|
332 (12.3)
|
213 (11.2)
|
47.1 (41.6–52.6)
|
52.7 (47.1–58.4)
| |
5.7 (3.1–8.3)
|
9.4 (6.0–12.8)
| |
|
III
|
634 (23.4)
|
507 (26.7)
|
64.9 (61.1–68.8)
|
72.8 (69.1–76.5)
| |
6.3 (4.3–8.2)
|
8.4 (6.0–10.7)
| |
|
IV
|
597 (22.1)
|
553 (29.2)
|
84.2 (81.2–87.1)
|
87.1 (84.2–89.9)
| |
5.8 (3.9–7.7)
|
6.5 (4.5–8.6)
| |
|
Surgery
| | | | |
< 0.001
| | |
< 0.001
|
|
No
|
886 (32.8)
|
806 (42.5)
|
82.1 (79.5–84.7)
|
85.9 (83.4–88.5)
| |
7.9 (6.1–9.7)
|
8.8 (6.8–10.8)
| |
|
Yes
|
1819 (67.2)
|
1091 (57.5)
|
34.1 (31.8–36.3)
|
41.7 (39.3–44.0)
| |
8.3 (7–9.6)
|
13.3 (11.6–15.0)
| |
- Abbreviations: Nt total number, Ne number of death events, ASC adenosquamous carcinoma, CI confidence interval, LC-SM lung cancer-specific mortality, OCSM other cause-specific morality, AJCC American Joint Committee on Cancer, IQR interquartile range
